Brief: Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
17/12/2025 14:38
Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O: STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY Source text: ID:nGNX7vjtC7 Further company coverage: GPCR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Structure Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure falls as investors await more obesity trial data, says Jefferies